ZURICH, Oct. 23, 2025 /PRNewswire/ — NLS Pharmaceutics Ltd. (Nasdaq: NLSP) (Nasdaq: NLSPW) (“NLS” or the “Company”), a Swiss clinical-stage biopharmaceutical company focused on central nervous system (“CNS”) disorders, and Kadimastem Ltd. (TASE: KDST) (“Kadimastem”), an advanced…
